Natural therapies
Time to start thinking “outside the tablet box”
From Mr I. Jackson, MRPharmS
I read with dismay Peter
Penson’s letter (PJ, 3 July, p21) concerning
the dubious nature of natural products. When he qualifies I suggest he
does three things:
(i) look at the shelves of the average pharmacy and
determine the evidence base behind many of the conventional medicines
he will be selling/dispensing;
(ii) visit his local hospital and witness
the
number of hospital admissions due to adverse reactions to conventional
drugs; and
(iii) take a trip to the Continent and see how natural therapies
are integrated into mainstream health care and community pharmacies.
Mr Penson talks about extracting the active ingredients from herbs
and marketing them as conventional pharmaceuticals. Many herbs contain
a
wide range of active ingredients which act in a variety of ways rather
than
just at one receptor — the concept of herbal polyvalency. A good
example would be mistletoe (Viscum album) which is one of the most widely
used oncological treatments in Germany. Its various active ingredients
prevent DNA/RNA synthesis, stimulate the production of natural T killer
cells and cytokines such as interleukins 1 and 6 and TNF-a. It works with
the body’s immune system rather than against it.
We spend less than 1 per cent of the NHS budget on alternative therapies.
This is hardly surprising when we have a Department of Health which
looks starry-eyed at the pharmaceutical industry, allowing patent extensions
through stereoisomers, oral melts and modified release formulations.
The US now spends $100m annually on randomised controlled trials into
natural medicines. I cannot find a figure for the UK. With 18 million
allergy suffers
in the UK and cancer rates increasing, I suggest that Mr Penson and
the rest of the professional start to “think outside the tablet box”. Ian Jackson
Mansfield, Nottinghamshire |